Biogen Inc (IDP.BE)
| Previous close | 208.40 |
| Open | 209.70 |
| Bid | 212.80 x 0 |
| Ask | 214.70 x 0 |
| Day's range | 207.90 - 214.30 |
| 52-week range | 177.95 - 266.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
Eisai and Biogen launch Alzheimer's drug Leqembi in China
Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Eisai has also collaborated with a major Chinese medical insurance firm to plan partial coverage of the drug cost, the companies said without naming the insurer. China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July.
- Zacks
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
- Zacks
Is the Options Market Predicting a Spike in Biogen (BIIB) Stock?
Investors need to pay close attention to Biogen (BIIB) stock based on the movements in the options market lately.
